Photo by bermixstudio from unsplash
In this issue of Blood, Frigault et al report that tisagenlecleucel, a CD19-specific chimeric antigen receptor (CAR) T-cell product, has a safety profile in a small series of patients with… Click to show full abstract
In this issue of Blood, Frigault et al report that tisagenlecleucel, a CD19-specific chimeric antigen receptor (CAR) T-cell product, has a safety profile in a small series of patients with aggressive B-cell non-Hodgkin lymphomas (B-NHLs) and secondary central nervous system (CNS) involvement similar to that seen in patients without active CNS disease.1 The Frigault et al study suggests that this product may benefit this previously excluded group of patients without an increased risk of neurotoxicity.
Keywords:
space cars;
cns safe;
safe space
Journal Title: Blood
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!